Allarity Therapeutics Inc

Change company Symbol lookup

Select an option...

ALLR Allarity Therapeutics Inc

SIVB SVB Financial Group

LYLT Loyalty Ventures Inc

NMRD Nemaura Medical Inc

LOGI Logitech International SA

BIOC Biocept Inc

KT KT Corp

SVRA Savara Inc

KA Kineta Inc

IMNM Immunome Inc

Go

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.